| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Qualification | |
| Date Qualified: | April 10, 2025 10:00 A.M. |
| Form: | 1-A POS |
| CIK: | 0001997296 |
| Company Name: | Medicus Pharma Ltd. |
| File Number: | 024-12573 |
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Medicus Pharma Ltd. (0001997296) (Issuer)
4 - Medicus Pharma Ltd. (0001997296) (Issuer)
4 - Medicus Pharma Ltd. (0001997296) (Issuer)
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su
PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs
PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn
EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)
S-3 - Medicus Pharma Ltd. (0001997296) (Filer)
SCHEDULE 13G/A - Medicus Pharma Ltd. (0001997296) (Subject)
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su
PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs
PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn